home2019-12-09T11:33:33+01:00

biomarkers for more stability in life

our purpose:
precision
medicine

discovery_and_validation_of_microRNA_biomarkers

TAmiRNA is a biotech company specialized in the discovery and validation of microRNA biomarkers. Our mission is to provide validated diagnostic solutions to patients with serious aging-related illnesses. We aim to improve and prolong patient stability, health and quality of life with increasing age.

our technology:
microRNA
signatures

mircoRNA_signatures

We are specialized in biomarker development using blood-circulating microRNAs – evolutionary conserved regulators of gene expression and cell/tissue function. We develop diagnostic algorithms (“signatures”) based on the logic combination of microRNA levels and clinical parameters.

our focus:
age-associated
diseases

age_associated_diseases

TAmiRNA is actively involved in R&D projects in osteoporosis (OP), cardio-vascular disease (CVD), liver disease and aging. OP and CVD are multifactorial illnesses. Using microRNA signatures we aim to decode the contributing disease factors on a personalized level, and to use this knowledge for better diagnosis.

biomarkers for more stability in life

our purpose:
precision
medicine

discovery_and_validation_of_microRNA_biomarkers

TamiRNA is a biotech company specialized in the discovery and validation of microRNA biomarkers. Our mission is to provide validated diagnostic solutions to patients with serious aging-related illnesses. We aim to improve and prolong patient stability, health and quality of life with increasing age.

our technology:
microRNA
signatures

mircoRNA_signatures

We are specialized in biomarker development using blood-circulating microRNAs – evolutionary conserved regulators of gene expression and cell/tissue function. We develop diagnostic algorithms (“signatures”) based on the logic combination of microRNA levels and clinical parameters.

our focus:
age-associated
diseases

TAmiRNA is actively involved in R&D projects in osteoporosis (OP), cardio-vascular disease (CVD), liver disease and aging. OP and CVD are multifactorial illnesses. Using microRNA signatures we aim to decode the contributing disease factors on a personalized level, and to use this knowledge for better diagnosis.

our products

osteomiR_microRNA_biomarkers_of_bone_quality
thrombomiR_microRNA_biomarkers_of_platelet_function

our products

osteomiR_microRNA_biomarkers_of_bone_quality
thrombomiR_microRNA_biomarkers_of_platelet_function

our services

microRNA services

services

Serum, plasma, urine, saliva, exosomes, cells, and tissues … We provide solutions for your biomarker discovery and validation needs in any biological matrix.

Kit services

Send us your samples to obtain results for osteomiR™, thrombomiR® or toxomiR® biomarkers by taking advantage of our in-house services.

Consultation

Take advantage of TAmiRNA´s deep expertise in RNA-based biomarker development.

Click_here_for_your_personalized_microRNA_service_offer

our services

microRNA services

services

Serum, plasma, urine, saliva, exosomes, cells, and tissues … We provide solutions for your biomarker discovery and validation needs.

One-Stop-Shop

Obtain results for osteomiR, thrombomiR,and toxomiR biomarkers in your samples by taking advantage of our inhouseservices.

Consultation

Take advantage of TAmiRNA´s deep expertise in RNA-based biomarker development.

Click_here_for_your_personalized_microRNA_service_offer

latest news

TAmiRNA at SOT 2020, 15-19 March 2020, Anaheim, California, USA

By |February 24th, 2020|Categories: biomarker, biomarkers, drug development, drug discovery, liquid biopsies, LMD, microRNAs, Personalized medicine|Tags: , , , , , , , , |

The sequencing advance allows genome scale analysis of miRNAs and promises a more efficient discovery approach for safety biomarkers, enabling retrospective analysis. Dr. Kseniya Khamina, TAmiRNA research scientist, will [...]

Read More
 0

New evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response

By |January 13th, 2020|Categories: biomarker, biomarkers, clopidogrel, diabetes, microRNAs, Personalized medicine, platelet activation, platelet-associated miRNAs, thrombomiR, type 2 diabetes mellitus|Tags: , , , , , , , , , |

We want to draw your attention to the latest publication of the King's College London, in Cardiovascular Diabetology. The research team provides new evidence for the clinical utility of [...]

Read More
 0

meet TAmiRNA 2020

By |January 1st, 2020|Categories: biomarker, biomarkers, microRNAs, Personalized medicine|Tags: , , , |

2020 TAmiRNA showcases at several conferences - take advantage, meet the TAmiRNA experts and discuss our latest developments and your needs! 2nd Longevity Therapeutics conference, 28-30 January 2020, San [...]

Read More
 0

TAmiRNA at SOT 2020, 15-19 March 2020, Anaheim, California, USA

By |February 24th, 2020|Categories: biomarker, biomarkers, drug development, drug discovery, liquid biopsies, LMD, microRNAs, Personalized medicine|Tags: , , , , , , , , |

The sequencing advance allows genome scale analysis of miRNAs and promises a more efficient discovery approach for safety biomarkers, enabling retrospective analysis. Dr. Kseniya Khamina, TAmiRNA research scientist, will deliver a presentation [...]

Read More
 0

New evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response

By |January 13th, 2020|Categories: biomarker, biomarkers, clopidogrel, diabetes, microRNAs, Personalized medicine, platelet activation, platelet-associated miRNAs, thrombomiR, type 2 diabetes mellitus|Tags: , , , , , , , , , |

We want to draw your attention to the latest publication of the King's College London, in Cardiovascular Diabetology. The research team provides new evidence for the clinical utility of platelet microRNA biomarkers [...]

Read More
 0

meet TAmiRNA 2020

By |January 1st, 2020|Categories: biomarker, biomarkers, microRNAs, Personalized medicine|Tags: , , , |

2020 TAmiRNA showcases at several conferences - take advantage, meet the TAmiRNA experts and discuss our latest developments and your needs! 2nd Longevity Therapeutics conference, 28-30 January 2020, San Francisco, California, USA [...]

Read More
 0
read more news
© Copyright TAmiRNA 2019 -